Ultragenyx (RARE) -44.7% to <meta name=

4.67 premarket Wed Sept 3 — Phase 3 Aspire study of apazunersen (GTX-102) in Angelman syndrome misses BOTH primary (Bayley-4 cognitive) and key secondary (MDRI) endpoints; company launches strategic review with expense cuts" /> 4.67 premarket Wed Sept 3 — Phase 3 Aspire study of apazunersen (GTX-102) in Angelman syndrome misses BOTH primary (Bayley-4 cognitive) and key secondary (MDRI) endpoints; company launches strategic review with expense cuts" />

Stock/TLDR — What Just Moved Markets: Earnings, Fed, M&A, MoversA high-volume feed of market-moving releases — quarterly earnings, FOMC decisions, M&A, regulatory actions, big single-name moves, macro prints, commodities and crypto — refreshed every 12 hours. Each release is explained in plain English so you actually understand what just happened and which tickers it touches.This site uses JavaScript to render the interactive feed. Enable JavaScript to use it.Stock/TLDR is not investment advice. Verify everything against primary sources before trading.